Cutaneous T Cell Lymphoma Outcomes Improved with Investigative BV Therapy in Phase 3 Clinical Trial
A study recently published in the journal Blood Advances has demonstrated that brentuximab vedotin (BV) treatment leads to improved outcomes for primary cutaneous anapestic large-cell lymphoma (C-ALCL) and CD30-expressing mycosis fungoides (MF)…